Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform

Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an angel financing round led by Cowin Capital. Other investors included HiMed Angel Fund and Joyin Center. Proceeds will go towards interventional ultrasound platform construction, product research and development, and manufacturing.

Company Focus and Technology
Hantong Medtech, focused on active interventional products, especially in the field of vascular interventional ultrasounds, boasts an in-house developed ultrasonic energy platform. The first ultrasound energy platform product is used for renal artery ultrasound ablation treatment of hypertension, covering host, algorithm, catheter, ultrasound transducer, and other core technologies. In addition, the company is developing the pulmonary embolism market.

Innovative Solutions and Market Potential
Its intravascular ultrasound-assisted drug thrombolytic system and catheter, combined with microbubbles, reduces the use of thrombolytic drugs by more than 95%, with an extremely low thrombosis recurrence rate. At the same time, the smaller catheter is easy to operate, without blood loss and pulmonary artery injury.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry